These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19901203)

  • 1. Left atrial appendage occlusion does not eliminate the need for warfarin.
    Whitlock RP; Healey JS; Connolly SJ
    Circulation; 2009 Nov; 120(19):1927-32; discussion 1932. PubMed ID: 19901203
    [No Abstract]   [Full Text] [Related]  

  • 2. Left atrial appendage occlusion eliminates the need for warfarin.
    Holmes DR; Schwartz RS
    Circulation; 2009 Nov; 120(19):1919-26; discussion 1926. PubMed ID: 19901202
    [No Abstract]   [Full Text] [Related]  

  • 3. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy.
    Viles-Gonzalez JF; Kar S; Douglas P; Dukkipati S; Feldman T; Horton R; Holmes D; Reddy VY
    J Am Coll Cardiol; 2012 Mar; 59(10):923-9. PubMed ID: 22381428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Reddy VY; Doshi SK; Sievert H; Buchbinder M; Neuzil P; Huber K; Halperin JL; Holmes D;
    Circulation; 2013 Feb; 127(6):720-9. PubMed ID: 23325525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter occlusion devices for the prevention of stroke in patients with atrial fibrillation.
    Lerakis S; Synetos A; Toutouzas K; Stefanadis C
    Hellenic J Cardiol; 2008; 49(1):33-6. PubMed ID: 18350780
    [No Abstract]   [Full Text] [Related]  

  • 6. Occlusion of left atrial appendage to treat atrial fibrillation.
    Calvert PA; Rana BS; Begley DA; Shapiro LM
    Lancet; 2009 Nov; 374(9703):1742-3; author reply 1743. PubMed ID: 19932351
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
    Ezekowitz MD; Kent AP
    Circulation; 2014 Oct; 130(17):1505-14. PubMed ID: 25332278
    [No Abstract]   [Full Text] [Related]  

  • 8. Left atrial appendage closure device in atrial fibrillation.
    Giudici MC; Bhave PD
    Card Electrophysiol Clin; 2015 Sep; 7(3):415-8. PubMed ID: 26304520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
    Berry C; Norrie J; McMurray JJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):149-51. PubMed ID: 16025234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WATCHMAN matches warfarin.
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):456. PubMed ID: 19419252
    [No Abstract]   [Full Text] [Related]  

  • 11. Left atrial appendage occlusion devices versus pharmacological agents for stroke prevention in atrial fibrillation: testing the noninferiority margins.
    Messori A; Fadda V; Maratea D; Trippoli S
    JACC Cardiovasc Interv; 2014 Aug; 7(8):942-3. PubMed ID: 25147042
    [No Abstract]   [Full Text] [Related]  

  • 12. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.
    Holmes DR; Reddy VY; Turi ZG; Doshi SK; Sievert H; Buchbinder M; Mullin CM; Sick P;
    Lancet; 2009 Aug; 374(9689):534-42. PubMed ID: 19683639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical and percutaneous left atrial appendage intervention: silent cerebral embolism considerations.
    Wang Z; Wang K; Lu S; Zhang L; Li M; Ju W; Ni B; Gu W; Shao Y; Chen M
    Eur J Cardiothorac Surg; 2023 Jun; 63(6):. PubMed ID: 36857577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous left atrial appendage transcatheter occlusion: an effective and safe protection against stroke or embolism?
    Stöllberger C; Finsterer J; Schneider B
    J Cardiovasc Electrophysiol; 2004 Mar; 15(3):373; author reply 373-4. PubMed ID: 15030433
    [No Abstract]   [Full Text] [Related]  

  • 15. Residual leaks following percutaneous left atrial appendage occlusion: assessment and management implications.
    Raphael CE; Friedman PA; Saw J; Pislaru SV; Munger TM; Holmes DR
    EuroIntervention; 2017 Nov; 13(10):1218-1225. PubMed ID: 28691914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left Atrial Appendage Closure Device in Atrial Fibrillation.
    Giudici MC; Bhave PD
    Cardiol Clin; 2017 May; 35(2):297-300. PubMed ID: 28411903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left Atrial Appendage Occlusion Devices Versus Pharmacological Agents for Stroke Prevention in Atrial Fibrillation.
    Messori A; Trippoli S
    J Am Coll Cardiol; 2015 Nov; 66(18):2056-2058. PubMed ID: 26516013
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply: Left Atrial Appendage Occlusion Devices Versus Pharmacological Agents for Stroke Prevention in Atrial Fibrillation.
    Holmes DR
    J Am Coll Cardiol; 2015 Nov; 66(18):2058. PubMed ID: 26516014
    [No Abstract]   [Full Text] [Related]  

  • 19. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation.
    Alli O; Doshi S; Kar S; Reddy V; Sievert H; Mullin C; Swarup V; Whisenant B; Holmes D
    J Am Coll Cardiol; 2013 Apr; 61(17):1790-8. PubMed ID: 23500276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left Atrial Appendage Occlusion Device and Novel Oral Anticoagulants Versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Briceno DF; Villablanca P; Cyrille N; Massera D; Bader E; Manheimer E; Aagaard P; Ferrick K; Gross J; Kim SG; Krumerman A; Palma E; Guttenplan N; Romero J; Fisher J; Garcia M; Natale A; Di Biase L
    Circ Arrhythm Electrophysiol; 2015 Oct; 8(5):1057-64. PubMed ID: 26226997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.